Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409741 | 1.00 | HDAC1 (0.59) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL5067786 | 1.00 | HDAC1 (0.59) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL2410014 | 0.91 | HDAC1 (0.46) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL2410017 | 0.91 | HDAC1 (0.46) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL17416782 | 0.87 | HDAC1 (0.52) | HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL14556142 | 0.87 | HDAC1 (0.52) | HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2410399 | 0.85 | HDAC1 (0.65) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL2413160 | 0.81 | HDAC1 (0.58) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL2413161 | 0.81 | HDAC1 (0.58) | HDAC1HDAC3CYP2C9SLC6A4SLC6A3 | |
| SCHEMBL17424661 | 0.78 | HDAC1 (0.50) | HDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | claimed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | claimed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | claimed |
| US-8354445-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-01-15 | — | — | US | disclosed |
| US-8030344-B2 | Such as (S)-2-(Dimethylamino)ethyl-1-(4-(2-aminophenylcarbamoyl)-phenyl)pyrrolidin-3-ylcarbamate for treating cell proliferative disorders | METHYLGENE INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| EP-2134680-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008109994-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227826-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC3 4/4885CYP2C9 4659/4885 |
| US-20110212965-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC3 4/4885CYP2C9 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.